A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase 3
Completed
NCT05305664
| Condition | Hyperlipoproteinemia |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Novartis Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 51 participants |
|---|
| Interventions | Pelacarsen (TQJ230) 80 mg s.c., Corresponding Placebo |
|---|
| Start date | Aug 19, 2022 |
|---|
| Completion date | Jan 28, 2025 |
|---|
| Results posted | Jul 17, 2026 |
|---|
Summary
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
Up to Week 52 · Apheresis sessions received per week
| Pelacarsen (TQJ230) | 0.16 Apheresis sessions received per week |
|---|
| Placebo | 0.93 Apheresis sessions received per week |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 0.006 (95% CI 0.003–0.013) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.